Shah, P I <br/><br/>
Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment.  [electronic resource] 

 -  The European respiratory journal  Jun 1995 
 - 954-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0903-1936 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Inhalation<br/>Adult<br/>Cystic Fibrosis--complications<br/>Deoxyribonuclease I--administration & dosage<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Male<br/>Recombinant Proteins--administration & dosage<br/>Respiratory Function Tests<br/>Respiratory Tract Infections--complications<br/>Severity of Illness Index<br/>Treatment Outcome